Vtesse

Vtesse, Inc. is a rare disease company dedicated to developing drugs for patients suffering from diseases that are underserved. Vtesse is working collaboratively with the National Institutes of Health (NIH) to advance clinical study of its lead compound for Niemann-Pick Type C1 Disease (NPC), and to conduct pre-clinical discovery and development of other novel drugs for NPC and other lysosomal storage diseases (LSDs). Vtesse is led by a highly experienced management team that has been involved in the development of more than 20 approved drugs and vaccines. Its experienced investor syndicate has committed initial funding that is expected to bring this compound through pivotal clinical trials. Vtesse is based in Gaithersburg, Maryland. Vtesse’s lead compound has shown promise in pre-clinical and clinical studies as a potential treatment for Niemann-Pick Disease Type C1. It is a well-characterized mixture of (2-hydroxypropyl)-beta-cyclodextrin that has been extensively evaluated in pre-clinical and clinical studies at the National Institutes of Health, as well as under individual compassionate use investigational new drug applications (iINDs) and in other academic labs. Vtesse has worked expediently with regulatory authorities, patient/parent organizations, physicians and other key stakeholders to start a Phase 2b/3 clinical trial to assess the efficacy of the compound for the treatment of NPC.